EcoDrugPlus

Cholinergic Receptor, Muscarinic 5a

Ensembl ID : ENSOSIG00000009479
Gene Symbol: CHRM5A
1 Cross references
195 Possible Orthologues:

Cholinergic Receptor, Muscarinic 5b

Ensembl ID : ENSOSIG00000009060
Gene Symbol: CHRM5B
1 Cross references
189 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 4b

Ensembl ID : ENSOSIG00000018753
Gene Symbol: CHRNA4B
1 Cross references
193 Possible Orthologues:

Cholinergic Receptor, Nicotinic, Alpha 7a (Neuronal)

Ensembl ID : ENSOSIG00000022872
Gene Symbol: CHRNA7A
1 Cross references
69 Possible Orthologues:

Coagulation Factor Ii (Thrombin) Receptor

Ensembl ID : ENSOSIG00000023758
Gene Symbol: F2R
1 Cross references
216 Possible Orthologues:

Coagulation Factor Ii Thrombin Receptor 2.1

Ensembl ID : ENSOSIG00000018033
Gene Symbol: F2R2.1
1 Cross references
263 Possible Orthologues:

Coagulation Factor Iii, Tissue Factor

Ensembl ID : ENSOSIG00000000033
Gene Symbol: F3
1 Cross references
199 Possible Orthologues:

Coagulation Factor Vii, Like

Ensembl ID : ENSOSIG00000010061
Gene Symbol: F7L
1 Cross references
78 Possible Orthologues:

Coagulation Factor X

Ensembl ID : ENSOSIG00000009825
Gene Symbol: F10
1 Cross references
240 Possible Orthologues:

Coiled-Coil Domain Containing 6a

Ensembl ID : ENSOSIG00000021471
Gene Symbol: CCDC6A
1 Cross references
207 Possible Orthologues:

Colony Stimulating Factor 1 Receptor

Ensembl ID : ENSOSIG00000006567
Gene Symbol: CSF1R
1 Cross references
204 Possible Orthologues:

Colony Stimulating Factor 1 Receptor, A

Ensembl ID : ENSOSIG00000021072
Gene Symbol: CSF1RA
1 Cross references
63 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).